The effect of famotidine, esomeprazole, and ezetimibe on levothyroxine absorption

Thyroid

Volumn 18, Issue 5, 2008, Pages 493-498

  Ananthakrishnan, Sonia ^a   Braverman, Lewis E ^a   Levin, Robert M ^a   Magnani, Barbarajean ^b   Pearce, Elizabeth N ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; EZETIMIBE; FAMOTIDINE; GASTRIN; LEVOTHYROXINE; LEVOTHYROXINE SODIUM; LIOTHYRONINE; THYROID HORMONE; THYROXINE;

AREA UNDER THE CURVE; ARTICLE; DRUG ABSORPTION; DRUG EFFECT; FREE THYROXINE INDEX; HORMONE BLOOD LEVEL; HUMAN; NORMAL HUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; STOMACH ACID SECRETION; STUDENT T TEST; THYROID DISEASE; THYROXINE BLOOD LEVEL; VOLUNTEER;

ADULT; ANTI-ULCER AGENTS; ANTICHOLESTEREMIC AGENTS; AZETIDINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FAMOTIDINE; FEMALE; HUMANS; INTESTINAL ABSORPTION; MALE; OMEPRAZOLE; RANDOM ALLOCATION; THYROXINE; TRIIODOTHYRONINE;

EID: 43449129176     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2007.0381     Document Type: Article

References (28)

1. Benvenga S, Bartolone L, Squadrito S, Lo Giudice F, Trimarchi F 1995 Delayed intestinal absorption of levothyroxine. Thyroid 5:249-253.
2. Sperber AD, Liel Y 1992 Evidence for interference with the intestinal absorption of levothyroxine by aluminum hydroxide. Arch Intern Med 152:183-184.
3. Sherman SI, Tielens ET, Ladenson PW 1994 Sucralfate causes malabsorption of L-thyroxine. Am J Med 96:531-535.
4. Northcutt RC, Stiel JN, Hollifield JW, Stant EG 1969 The influence of cholestyramine on thyroxine absorption. JAMA 208:1857-1861.
5. Singh N, Singh PN, Hershman JM 2000 Effect of calcium carbonate on the absorption of levothyroxine. JAMA 283:2822-2825.
6. Campbell NRC, Hasinoff BB, Stalts H, Rao B, Wong NC 1992 Ferrous sulfate reduces thyroxine efficacy in patients with hypothyroidism. Ann Intern Med 117:1010-1013.
7. Centanni M, Gargano L, Canettieri G, Viceconti N, Franchi A, Della Fave G, Annibale B 2006 Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis. N Engl J Med 354:1787-1795.
8. Dietrich JW, Gieselbrecht K, Holl RW, Boehm BO 2006 Absorption kinetics of levothyroxine is not altered by proton-pump inhibitor therapy. Horm Metab Res 38:57-59.
9. Bell NJV, Burget D, Howden CW, Wilkinson J, Hunt RH 1992 Appropriate acid suppression for the management of gastroesophageal reflux disease. Digestion 51:59-67.
10. Lind T, Rydberg L, Kyleback A, Jonsson A, Andersson T, Hasselgren T, Holmberg J, Rohss K 2000 Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 14:861-867.
11. Esomeprazole magnesium (Nexium) [package insert]. Wilmington, DE: AstraZeneca, 2005.
12. Famotidine (Pepcid) [package insert]. Whitehouse Station, NJ: Merck & Co. Inc., 2001.
13. Siraj ES, Gupta MK, Reddy SSK 2003 Raloxifene causing malabsorption of levothyroxine. Arch Intern Med 163:1367-1370.
14. Singh N, Weisler SL, Hershman JM 2001 The acute effect of calcium carbonate on the intestinal absorption of levothyroxine. Thyroid 11:967-971.
15. Blakesley V, Awni W, Locke C, Ludden T, Granneman GR, Braverman LE 2004 Are bioequivalence studies of levothyroxine sodium formulations in euthyroid volunteers reliable? Thyroid 14:195-204.
16. Bonapace ES, Fisher RS, Parkman HP 2000 Does fasting serum gastrin predict gastric acid suppression in patients on proton-pump inhibitors? Dig Dis Sci 45:34-39.
17. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC 2000 The Colorado thyroid disease prevalence study. Arch Intern Med 160:526-534.
18. Sawin CT, Geller A, Wolf PA, Belanger AJ, Baker E, Bacharach P, Wilson PW, Benjamin EJ, D'Agostino RB 1994 Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 331:1249-1252.
19. Auer J, Scheibner P, Mische T, Langsteger W, Eber O, Eber B 2001 Subclinical hyperthyroidism as a risk factor for atrial fibrillation. Am Heart J 142:838-842.
20. Papi G, Pearce EN, Braverman LE, Betterle C, Roti E 2005 A clinical and therapeutic approach to thyrotoxicosis with thyroid-stimulating hormone suppression only. Am J Med 118:349-361.
21. Cooper DS 2001 Clinical practice. Subclinical hypothyroidism. N Engl J Med 345:260-265.
22. Sachmechi I, Reich DM, Aninyei M, Wibowo F, Gupta G, Kim PJ 2007 Effect of proton pump inhibitors on serum thyroidstimulating hormone level in euthyroid patients treated with levothyroxine for hypothyroidism. Endocr Pract 13:345-349.
23. Singer DA, Cooper DS, Levy EG, Ladenson PW, Braverman LE, Daniels G, Greenspan FS, McDougal IR, Nicolai TF 1995 Treatment guidelines for patients with hyperthyroidism and hypothyroidism. Standards of Care Committee, American Thyroid Association. JAMA 273:808-812.
24. Sudhop T, Lutjohann D, Kodal A 2002 Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 106:1943-1948.
25. Knopp RH, Bays H, Manion CV, Lipka LJ, Melani L, LeBeaut AP, Suresh R, Veltri EP 2001 The Ezetimibe Study Group. Effect of ezetimibe on serum concentrations of lipidsoluble vitamins. Atherosclerosis 2(Suppl):90.
26. John-Kalarickal J, Pearlman G, Carlson HE 2007 New medications which decrease levothyroxine absorption. Thyroid 17:763-765.
27. US Department of Health and Human Services, FDA, CDER 2000 Guidelines for industry: levothyroxine sodium tablets - in vivo pharmacokinetic and bioavailability studies and in vitro dissolution testing. December 2000. http://www.fda.gov/cder/guidance/3645fnl.htm
28. Checchi S, Montanaro A, Pasqui L, Ciuoli C, De Palo V, Chiappetta MC, Pacini F 2008 L-thyroxine requirement in patients with autoimmune hypothyroidism and parietal cell antibodies. J Clin Endocrinol Metab 93:465-469.